Precision respiratory medicine and the microbiome

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

A decade of rapid technological advances has provided an exciting opportunity to incorporate information relating to a range of potentially important disease determinants in the clinical decision-making process. Access to highly detailed data will enable respiratory medicine to evolve from one-size-fits-all models of care, which are associated with variable clinical effectiveness and high rates of side-effects, to precision approaches, where treatment is tailored to individual patients. The human microbiome has increasingly been recognised as playing an important part in determining disease course and response to treatment. Its inclusion in precision models of respiratory medicine, therefore, is essential. Analysis of the microbiome provides an opportunity to develop novel prognostic markers for airways disease, improve definition of clinical phenotypes, develop additional guidance to aid treatment selection, and increase the accuracy of indicators of treatment effect. In this Review we propose that collaboration between researchers and clinicians is needed if respiratory medicine is to replicate the successes of precision medicine seen in other clinical specialties.

LanguageEnglish
Pages73-82
Number of pages10
JournalThe Lancet Respiratory Medicine
Volume4
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{16840d9bb7214aaebd2a0bd47b23fecf,
title = "Precision respiratory medicine and the microbiome",
abstract = "A decade of rapid technological advances has provided an exciting opportunity to incorporate information relating to a range of potentially important disease determinants in the clinical decision-making process. Access to highly detailed data will enable respiratory medicine to evolve from one-size-fits-all models of care, which are associated with variable clinical effectiveness and high rates of side-effects, to precision approaches, where treatment is tailored to individual patients. The human microbiome has increasingly been recognised as playing an important part in determining disease course and response to treatment. Its inclusion in precision models of respiratory medicine, therefore, is essential. Analysis of the microbiome provides an opportunity to develop novel prognostic markers for airways disease, improve definition of clinical phenotypes, develop additional guidance to aid treatment selection, and increase the accuracy of indicators of treatment effect. In this Review we propose that collaboration between researchers and clinicians is needed if respiratory medicine is to replicate the successes of precision medicine seen in other clinical specialties.",
author = "Geraint Rogers and Steven Wesselingh",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/S2213-2600(15)00476-2",
language = "English",
volume = "4",
pages = "73--82",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "1",

}

Precision respiratory medicine and the microbiome. / Rogers, Geraint; Wesselingh, Steven.

In: The Lancet Respiratory Medicine, Vol. 4, No. 1, 01.01.2016, p. 73-82.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Precision respiratory medicine and the microbiome

AU - Rogers, Geraint

AU - Wesselingh, Steven

PY - 2016/1/1

Y1 - 2016/1/1

N2 - A decade of rapid technological advances has provided an exciting opportunity to incorporate information relating to a range of potentially important disease determinants in the clinical decision-making process. Access to highly detailed data will enable respiratory medicine to evolve from one-size-fits-all models of care, which are associated with variable clinical effectiveness and high rates of side-effects, to precision approaches, where treatment is tailored to individual patients. The human microbiome has increasingly been recognised as playing an important part in determining disease course and response to treatment. Its inclusion in precision models of respiratory medicine, therefore, is essential. Analysis of the microbiome provides an opportunity to develop novel prognostic markers for airways disease, improve definition of clinical phenotypes, develop additional guidance to aid treatment selection, and increase the accuracy of indicators of treatment effect. In this Review we propose that collaboration between researchers and clinicians is needed if respiratory medicine is to replicate the successes of precision medicine seen in other clinical specialties.

AB - A decade of rapid technological advances has provided an exciting opportunity to incorporate information relating to a range of potentially important disease determinants in the clinical decision-making process. Access to highly detailed data will enable respiratory medicine to evolve from one-size-fits-all models of care, which are associated with variable clinical effectiveness and high rates of side-effects, to precision approaches, where treatment is tailored to individual patients. The human microbiome has increasingly been recognised as playing an important part in determining disease course and response to treatment. Its inclusion in precision models of respiratory medicine, therefore, is essential. Analysis of the microbiome provides an opportunity to develop novel prognostic markers for airways disease, improve definition of clinical phenotypes, develop additional guidance to aid treatment selection, and increase the accuracy of indicators of treatment effect. In this Review we propose that collaboration between researchers and clinicians is needed if respiratory medicine is to replicate the successes of precision medicine seen in other clinical specialties.

UR - http://www.scopus.com/inward/record.url?scp=84952988286&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(15)00476-2

DO - 10.1016/S2213-2600(15)00476-2

M3 - Review article

VL - 4

SP - 73

EP - 82

JO - The Lancet Respiratory Medicine

T2 - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 1

ER -